A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Lower Blood Sugar in People With Type 2 Diabetes
- Disease/Condition
- Diabetes Mellitus, Type 2
- Drug/Device/Intervention
- NNC0519-0130
- Study type
- Interventional
- Intervention type
- drug
- Primary sponsor
- Novo Nordisk A/S
- Location
- Chula Vista,Fresno,Fresno,La Mesa,Lancaster,Lomita,Los Alamitos,Montclair,Toluca Lake,Torrance,Tustin,Aurora,Clearwater,Miami,Columbus,Blackfoot,Peoria,Oxon Hill,Rockville,Springfield,Butte,Las Vegas,, Australia,Canada,India,Japan,South Africa,South Korea,United States of America
- Phase
- Phase 2
- Start date
- Mar 18, 2024
- End date
- Aug 26, 2025
- Enrollment
- 288 participants
Change in Glycated haemoglobin (HbA1c)
This study will look at how well a new medicine called NNC0519-0130 helps people with type 2
 diabetes lower their blood sugar and body weight. The study will test up to 7 different doses
 of NNC0519-0130. Which treatment participant will get is decided by chance. Participants will
 take 1-3 injections once a week. The study medicine will be injected under skin with a thin
 needle in the stomach, thigh, or upper arm. The study will last for about 40 weeks.
- Registry
- ClinicalTrials.gov
- Trial ID
- NCT06326047
- Type
- Non-Device Trial
Access comprehensive clinical trial information for NCT06326047 through Pure Global AI's free database. This Phase 2 trial is sponsored by Novo Nordisk A/S and is currently Recruiting. The study focuses on Diabetes Mellitus, Type 2. Target enrollment is 288 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.